



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/669,154	09/23/2003	Avram Schciner	279.608US1	1665
21186 7590 02/02/2007 SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. BOX 2938 MINNEAPOLIS, MN 55402			EXAMINER HELLER, TAMMIE K	
			ART UNIT 3766	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE			MAIL DATE	DELIVERY MODE
3 MONTHS			02/02/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

NT

Office Action Summary	Application No. 10/669,154	Applicant(s) SCHEINER, AVRAM	
	Examiner Tammie Heller	Art Unit 3766	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 November 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3, 6-9, 11-13, 16 and 17 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 6-9, 11-13, 16 and 17 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. The amendment filed on November 17, 2006 has been received and considered. By this amendment, claims 1, 8, and 11 have been amended, claims 5, 10, and 15 have been cancelled, and claims 1-3, 6-9, 11-13, 16 and 17 are now pending in the application.

Response to Arguments

2. Applicant's arguments filed November 17, 2006 have been fully considered but they are not persuasive. Regarding the rejection of the claims under 35 USC 102(e) as being anticipated by Casavant, Applicant argues that Casavant fails to disclose a means for detecting the presence of respiratory activity. However, at step 280 of Figure 7, Casavant discloses detecting the oxygen saturation or pressure of the patient. As is well known in the art, oxygen saturation and pressure are both measures that may serve as indicators of the respiratory activity of a patient. Therefore, Casavant does detect the presence of respiratory activity of a patient.

3. Regarding the rejection of the claims under 35 USC 103(a) as being unpatentable over Scheiner in view of Min, Applicant argues that neither Scheiner nor Min discloses delivering diaphragmatic stimulation after a capacitor has finished charging and respiratory arrest has been detected. However, Min in fact discloses a system which correlates the delivery of a cardioversion therapy to an optimum phase of the respiratory cycle which includes a controller which charges an output capacitor when ventricular fibrillation is detected, monitors respiratory activity while the output capacitor is charging, delivers diaphragmatic stimulation if respiratory arrest is detected

and only if the output capacitor has not finished charging, and delivers a shock pulse after the output capacitor is charged (see col. 6, ln. 9-22). The controller of Min is utilized in order to effect delivery of therapy when the impedance between the stimulation electrodes is minimized (see col. 1, ln. 28-29).

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. Claims 1-3, 6-9, 11-13, 16 and 17 are rejected under 35 U.S.C. 102(e) as being anticipated by Casavant. Regarding claim 1, Casavant discloses an implantable medical device for diaphragmatic stimulation which includes ventricular sensing and shock channels (see paragraph 28, ln. 4-10 and paragraph 48, ln. 12-14), a controller 114 (see paragraph 6, ln. 1-3 and paragraph 57, ln. 1-4), and thoracic impedance and diaphragmatic pacing channels (see paragraph 16 and paragraph 48, ln. 12-14). Further, the controller of Casavant is programmed to begin charging an output capacitor of the ventricular shock channel when ventricular fibrillation is detected, deliver diaphragmatic pacing if respiratory arrest is detected and only if the output capacitor has not finished charging, and deliver a shock pulse after the output capacitor is charged (see Figure 5). At paragraph 34, Casavant discloses that stimulation is applied

to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the apparatus of Casavant inherently detects respiratory activity in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further, at step 280 of Figure 7, Casavant discloses detecting the oxygen saturation or pressure of the patient. As is well known in the art, oxygen saturation and pressure are both measures that may serve as indicators of the respiratory activity of a patient. Therefore, Casavant does detect the presence of respiratory activity of a patient.

6. Regarding claim 2, Casavant discloses that the diaphragmatic pacing channel may also be used to deliver cardiac pacing pulses (see paragraph 48, ln. 11-12).

7. Regarding claim 3, Casavant discloses that the diaphragmatic pacing pulses may be applied at an amplitude of 20 volts (see paragraph 59, ln. 9-10), which is within the range of 10 to 30 volts.

8. Regarding claim 6, Casavant discloses that a diaphragmatic pacing pulse may be delivered during a ventricular refractory period of a ventricular sense (see paragraph 36, ln. 16-19).

9. Regarding claim 7, as previously discussed, at paragraph 34, Casavant discloses that stimulation is applied to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the controller of Casavant is inherently programmed to monitor for respiratory activity after successful termination of the ventricular fibrillation by the shock pulse in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further,

Casavant discloses that a diaphragmatic pacing pulse may be delivered during a ventricular refractory period of a ventricular sense (see paragraph 36, ln. 16-19).

10. Regarding claim 8, Casavant discloses an implantable medical device for diaphragmatic stimulation which includes ventricular sensing and shock channels (see paragraph 28, ln. 4-10 and paragraph 48, ln. 12-14), a controller 114 (see paragraph 6, ln. 1-3 and paragraph 57, ln. 1-4), and thoracic impedance and diaphragmatic pacing channels (see paragraph 16 and paragraph 48, ln. 12-14). Further, the controller of Casavant is programmed to begins charging an output capacitor of the ventricular shock channel when ventricular fibrillation is detected, deliver diaphragmatic pacing if respiratory arrest is detected and only if the output capacitor has not finished charging, and deliver a shock pulse after the output capacitor is charged (see Figure 5). At paragraph 34, Casavant discloses that stimulation is applied to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the apparatus of Casavant inherently detects respiratory activity in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further, at step 280 of Figure 7, Casavant discloses detecting the oxygen saturation or pressure of the patient. As is well known in the art, oxygen saturation and pressure are both measures that may serve as indicators of the respiratory activity of a patient. Therefore, Casavant does detect the presence of respiratory activity of a patient.

11. Regarding claim 9, as previously discussed, at paragraph 34, Casavant discloses that stimulation is applied to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the controller of

Casavant is inherently programmed to monitor for respiratory activity after successful termination of the ventricular fibrillation by the shock pulse in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further, Casavant discloses that a diaphragmatic pacing pulse may be delivered during a ventricular refractory period of a ventricular sense (see paragraph 36, ln. 16-19).

12. Regarding claim 11, Casavant discloses an implantable medical device that performs the method of monitoring a ventricular sensing channel in order to detect ventricular fibrillation (see paragraph 28, ln. 4-10 and paragraph 48, ln. 12-14), begin charging an output capacitor of the ventricular shock channel when ventricular fibrillation is detected (see step 244 in Figure 5), delivering diaphragmatic pacing upon detection of respiratory arrest only if the output capacitor is not finished charging (see step 246 in Figure 5), and delivering shock therapy through a ventricular shock channel after the output capacitor has charged (see step 250 in Figure 5). At paragraph 34, Casavant discloses that stimulation is applied to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the apparatus of Casavant inherently detects respiratory activity in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further, at step 280 of Figure 7, Casavant discloses detecting the oxygen saturation or pressure of the patient. As is well known in the art, oxygen saturation and pressure are both measures that may serve as indicators of the respiratory activity of a patient. Therefore, Casavant does detect the presence of respiratory activity of a patient.

13. Regarding claim 12, Casavant discloses that the diaphragmatic pacing is delivered as pacing pulses to the phrenic nerve (see paragraph 36, ln. 16-19).

14. Regarding claim 13, Casavant discloses that the diaphragmatic pacing pulses may be applied at an amplitude of 20 volts (see paragraph 59, ln. 9-10), which is within the range of 10 to 30 volts.

15. Regarding claim 16, Casavant discloses delivering diaphragmatic pacing through a cardiac pacing channel (see Figure 1).

16. Regarding claim 17, as previously discussed, at paragraph 34, Casavant discloses that stimulation is applied to the phrenic nerves in order to facilitate a more normal respiration pattern. Therefore, the Examiner takes the position that the controller of Casavant is inherently programmed to monitor for respiratory activity after successful termination of the ventricular fibrillation by the shock pulse in order to determine the rate and level of the phrenic nerve stimulation (see paragraph 73 and 74). Further, Casavant discloses that a diaphragmatic pacing pulse may be delivered during a ventricular refractory period of a ventricular sense (see paragraph 36, ln. 16-19).

Claim Rejections - 35 USC § 103

17. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

18. Claims 1-3, 5-13, and 15-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scheiner in view of Min et al. (U.S. Patent No. 5,836,976, cited by applicant), herein Min. Regarding claims 1, 8, and 11, Scheiner discloses a method and apparatus for diaphragmatic pacing which includes ventricular sensing and shock channels (see col. 3, ln. 59-60 and col. 4, ln. 3-7), a controller (see col. 5, ln. 63-67 and col. 6, ln. 1-3), and thoracic impedance and diaphragmatic pacing channels (see col. 5, ln. 65-67 and col. 6, ln. 1-3). Further, the controller of Scheiner is programmed to deliver a shock pulse when ventricular fibrillation is detected and deliver a diaphragmatic pacing pulse when no respiratory activity is detected (see col. 6, ln. 9-14 and 19-21). Scheiner fails to disclose charging an output capacitor when ventricular fibrillation is detected, monitoring respiratory activity while the output capacitor is charging, delivering diaphragmatic stimulation if respiratory arrest is detected and only if the output capacitor has not finished charging, and delivering a shock pulse after the output capacitor is charged. Min discloses a system which correlates the delivery of a cardioversion therapy to an optimum phase of the respiratory cycle which includes a controller which charges an output capacitor when ventricular fibrillation is detected, monitors respiratory activity while the output capacitor is charging, delivers

diaphragmatic stimulation if respiratory arrest is detected and only if the output capacitor has not finished charging, and delivers a shock pulse after the output capacitor is charged (see col. 6, ln. 9-22). The controller of Min is utilized in order to effect delivery of therapy when the impedance between the stimulation electrodes is minimized (see col. 1, ln. 28-29). Therefore, it would have been obvious to one having ordinary skill in the art at the time of the invention to utilize the controller and control steps taught by Min, in the method and apparatus of Scheiner, in order to effect delivery of therapy when the impedance between the stimulation electrodes is minimized.

19. Regarding claim 2, Scheiner discloses that the diaphragmatic pacing channel may also be used to deliver cardiac pacing pulses (see col. 4, ln. 7-9).

20. Regarding claims 3 and 13, Scheiner discloses that the diaphragmatic pacing pulse is on the order of 0.2 to 14 volts (see col. 4, ln. 62-65), which is within the range of 10 to 30 volts.

21. Regarding claims 5, 10, and 15, the control steps taught by Min include delivering a diaphragmatic pacing pulse when both respiratory arrest and ventricular fibrillation are detected only after one or more shock pulses are unsuccessful in termination the ventricular fibrillation (see Figure 5).

22. Regarding claim 6, Scheiner discloses that a diaphragmatic pacing pulse may be delivered during a ventricular refractory period after a ventricular sense (see col. 9, ln. 29-30).

23. Regarding claims 7, 9, and 17, Scheiner illustrates in Figure 7 that a diaphragmatic pacing pulse may be delivered during ventricular fibrillation while the

device prepares to deliver a shock pulse. Further, the control steps taught by Min include monitoring for respiratory activity after successful termination of the ventricular fibrillation by the shock pulse and delivering a diaphragmatic pacing pulse during a ventricular refractory period after a ventricular sense if respiratory arrest is detected.

24. Regarding claim 12, Scheiner discloses that the diaphragmatic pacing is delivered as pacing pulses to the phrenic nerve (see col. 3, ln. 43).

25. Regarding claim 16, Scheiner discloses delivering diaphragmatic pacing through a cardiac pacing channel (see Figures 1A and 1B).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tammie Heller whose telephone number is 571-272-1986. The examiner can normally be reached on Monday through Friday from 7am until 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert E. Pezzuto can be reached on 571-272-6996. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Tammie K. Heller
Patent Examiner
Art Unit 3766



Robert E. Pezzullo
Supervisory Patent Examiner
Art Unit 3766